2022 WHO Biosimilar Guideline improves access, IGBA says

Under the revised 2022 WHO Biosimilars Guideline, IGBA says regulatory authorities can confidently revaluate biosimilar access requirements.

Related Keywords

Vivian Frittelli ,Julie Mar ,Biosimilars Committee ,World Health Organization ,International Generic ,Biosimilar Medicines Association ,Embracing Science ,Biosimilars Guideline ,Access Policy Blueprint ,Regulatory Efficiency ,